Cost comparisons of seven leading brands of the Hypolipidemic drug, Rosuvastatin available in an India city
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20192621Keywords:
Cost per year, Hypolipidemic drugs, Pharmaco economics, Rosuvastatin ten milligramAbstract
Background: Hypolipidemic drugs need to be prescribed lifelong for most of the selected patients, once started. Price variation can lead to huge financial strain on the patients, especially when cost associated issues are not considered by the prescribing medical practitioner. This study was conducted to compare the cost, to the patient, of seven most commonly prescribed preparations of different brands of Rosuvastatin ten milligram, in Kolhapur city.
Methods: Authors purchased a strip of 10 capsules each of the seven leading brands of Rosuvastatin ten milligrams. The prices of the strip of 10 capsules of each of the seven chosen brands were compared. Finally, the cost of each of these seven brands for one year, was compared directly as well as using percentages. The data was collected, analysed and presented in tabular forms and figures.
Results: The data of the cost of seven different brands of a single hypolipidemic drug, Rosuvastatin ten milligram shows that the cost of the costliest among the seven brands of this drug for one year is almost two times that of the cheapest brand, or in other words almost 200 percent that of the cheapest brand.
Conclusions: The cost differences between the cheapest and the costliest brands were substantial. The cost of remaining five brands was dispersed in between these two extremes. India, with a major part of the population being highly concerned about the cost of medications, the prescribing medical practitioner must select the preparation wisely . The most costly preparation of Rosuvastatin ten milligram can substantially add to the financial strain on the patient’s yearly expenses. Thus, Pharmaco economic considerations must be a prime concern while making a decision to prescribe medicines, especially in a country like India.
References
Mamatha K, Vishnu K. Cost variation analysis of various brands of oral hypolipidemic drugs available in Indian pharmaceutical market. Int J Res Pharmacol Pharmacotherapeut. 2017;6(3):381-88.
Menon A, Kotwal N, Singh Y, Girish R. Statins: Choleaterol guidelines and Indian perspective. Indian J Endocrinol Metabol. 2015;19(5):546-53.
Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292(5519):1160-4.
DPCO, Drug Price Control Order 2013 - National Pharmaceutical Pricing Authority; 2013. Available at: http://www.arthapedia.in
Harvard School of Public Health, Boston, MA, USA. How Effective Is India's Drug Price Control Regime? 2007. Available at: https://cdn1.sph.harvard.edu/wp-content/uploads/sites/114/2012/10/RP256.pdf.
Sahay A, Jaikumar S. Does pharmaceutical price regulation result in greater access to essential medicines? Study of the impact of drug price control order on sales volume of drugs in India. 2014;34(4):64-65.
DPCO Impact: Pharma cos growth suffers for drugs under price ceiling/ Business Standard News, 2013. Available at: https://www.business-standard.com/article/companies/dpco-impact-pharma-cos-growth-suffers-for-drugs-under-price-ceiling-113081800677_1.html.
Vernon JA, Golec JH, Hughen WK. The economics of pharmaceutical price regulation and importation: refocusing the debate. Am J Law Med. 2006;32(2-3):175-92.
Balarajan Y, Selvaraj S, Subramanian SV. Health care and equity in India. Lancet. 2011;377(9764):505-15.
Kojima G, Bell C, Masaki K. Reducing cost by reducing polypharmacy: The polypharmacy Outcomes project. J Am Med Directors Asso. 2012;13(9):818.e11-e17.
